Michelle Mitchell: Cancer Research UK Engages With New National Cancer Board
Michelle Mitchell: Cancer Research UK Engages With New National Cancer Board Oncodaily
Онкология
Исследования и наука
1636 материалов по теме, собраны автоматически из проверенных источников
Онкология
'Plug-and-play' CAR T technology adapts as cancer changes
Researchers from City of Hope have developed a new "plug-and-play" technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. Published in Cancer Immunology Research, the…
🎗️
Онкология
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 Business Wire
Онкология
What drives time-to-randomization in oncology trials?
What drives time-to-randomization in oncology trials? clinicaltrialsarena.com
Онкология
CU Anschutz Thyroid Cancer Researchers Get Major Boost from DOD Impact Award
CU Anschutz Thyroid Cancer Researchers Get Major Boost from DOD Impact Award University of Colorado Anschutz
🎗️
Онкология
Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion
Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion streetinsider.com
Онкология
Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion
Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion PR Newswire
Онкология
A head-and-neck cancer trial reported 39.3 months of median survival
A head-and-neck cancer trial reported 39.3 months of median survival Stock Titan
Онкология
What drives time-to-randomization in oncology trials?
What drives time-to-randomization in oncology trials? Pharmaceutical Technology
🎗️
Онкология
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESM
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESM Business Wire
Онкология
Ivonescimab beats durvalumab in biliary tract cancer Phase III trial
Ivonescimab beats durvalumab in biliary tract cancer Phase III trial The Clinical Trial Vanguard
Онкология
VHIO celebrates 20 years of driving cancer research
VHIO celebrates 20 years of driving cancer research VHIO
Онкология
UMich launches world’s first histotripsy center, advancing non-invasive cancer treatment research
UMich launches world’s first histotripsy center, advancing non-invasive cancer treatment research The Michigan Daily
Онкология
Study unveils ‘plug-and-play’ CAR T technology designed to adapt as cancer changes
Study unveils ‘plug-and-play’ CAR T technology designed to adapt as cancer changes EurekAlert!
Онкология
How AI Is Influencing Cancer Research and Care Delivery - Sarah Cannon Research Institute
How AI Is Influencing Cancer Research and Care Delivery - Sarah Cannon Research Institute Oncodaily
‹
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
›